Objectives In non-small cell lung cancer (NSCLC), the association between common EGFR
mutations (Del EX19/L858R) with EGFR tyrosine kinase inhibitors (EGFR-TKIs) has been …

The efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) in
patients with non-small cell lung cancer (NSCLC) is related to EGFR mutations. Although the …

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‑TKI) is the first‑line
treatment for patients with advanced non‑small‑cell lung cancer (NSCLC) who have an …

Non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation is
sensitive to EGFR tyrosine kinase inhibitors (TKIs). But little is known about the response to …

Background EGFR mutations cause inconsistent response to EGFR tyrosine-kinase
inhibitors (TKI). To better understand these features, we reviewed all cases of EGFR …

Objective Data on the clinical activity of epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) in patients with non-small-cell lung cancer (NSCLC) and uncommon …

Mutations in exons 18–21 of the epidermal growth factor receptor gene (EGFR) can confer
sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small-cell …

Background Molecular characterization of non–small-cell lung cancer (NSCLC), defined
predictive and druggable mutations that greatly modified patient prognoses. The most …

Introduction There are a number of uncommon EGFR mutations whose associations with
TKIs are not well clarified. Here, we summarize the clinical data of patients with multiple …

Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are
standard of care for patients with EGFR mutation-positive non–small-cell lung cancer …